1 results match your criteria: "and Suzhou Institute of Blood and Marrow Transplantation[Affiliation]"
Addition of Cladribine to Idarubicin and Cytarabine during Induction Increases the Overall Efficacy Rate in Adult Patients with Acute Myeloid Leukemia: A Matched-Pair Retrospective Comparison.
Chemotherapy
April 2016
Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, and Collaborative Innovation Center of Hematology, Soochow University, and Suzhou Institute of Blood and Marrow Transplantation, and Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.
Objectives: The aims of this study were to evaluate a novel induction regimen composed of idarubicin (IDA), cytarabine (Ara-C) and cladribine (IAC regimen) for acute myeloid leukemia (AML) patients, and to identify the prognostic factors affecting treatment outcomes.
Methods: The clinical data of 27 untreated AML patients who received the IAC regimen as primary induction therapy in our hospital between April and November 2014 were analyzed retrospectively. The treatment outcomes of the IAC regimen were compared with two IA (IDA + Ara-C) regimens (IDA 10 mg/m² and IDA 12 mg/m²) in a pair-matched analysis.